Abstract：【Objective】 This study aimed to assess the therapeutic efficacy of combining amlodipine with atorvastatin calcium in patients with concurrent hypertension and coronary heart disease(CHD).【Methods】 A total of 300 patients with coexisting hypertension and CHD, treated at our hospital from January 2022 to December 2024, were selected. They were randomly assigned into two groups of 150 patients each. The control group received standard treatment with amlodipine and fluvastatin sodium, whereas the intervention group was treated with amlodipine in combination with atorvastatin calcium. Key clinical indicators, including blood pressure [systolic blood pressure(SBP), diastolic blood pressure(DBP)], lipid profiles [total cholesterol(TC), triglycerides(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C)], cardiac function [cardiac index(CI), cardiac output(CO), left ventricular ejection fraction(LVEF)], endothelial function [nitric oxide(NO), endothelin-1(ET-1)], and inflammatory markers [C-reactive protein(CRP), homocysteine(Hcy)], were compared between the two groups.【Results】 After treatment, SBP and DBP in both groups were lower than before treatment, with statistically significant differences(P<0.05). And the intervention group showed significantly lower systolic and diastolic blood pressure levels compared to the control group(P<0.05). Serum TC, TG, and LDL-C levels in both groups were lower than before treatment, while the intervention group demonstrated lower levels of TC, TG, and LDL-C, and higher levels of HDL-C(P<0.05) compare to the control group. After treatment, LVEF, CI, and CO levels in both groups were higher than before treatment, with the observation group having a higher level than the control group(P<0.05). After treatment, serum NO levels in both groups were higher than before treatment, with the observation group having a higher level than the control group. Serum ET-1 levels and IMT were lower than before treatment, with the observation group having a lower level than the control group(P<0.05). Serum CRP and Hcy levels in both groups were lower than before treatment, with the observation group having a lower level than the control group(P<0.05).【Conclusion】 The combined use of amlodipine and atorvastatin calcium offers superior benefits in managing both hypertension and lipid levels, while also improving cardiac and endothelial function and attenuating systemic inflammation. This regimen presents a promising approach in the clinical management of patients with coexisting hypertension and CHD.
2025, Vol. 42 
